The historical data trend for Nxera Pharma Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:JSS vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Nxera Pharma Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nxera Pharma Co Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Nxera Pharma Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nxera Pharma Co (FRA:JSS) has a Buyback Yield % of 0.00 as of Jul. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nxera Pharma Co and its competitors. According to the industry distribution chart, Nxera Pharma Co ranks #999999 out of 744 companies in the Biotechnology industry.
Is Nxera Pharma Co's Buyback Yield % too high?
Nxera Pharma Co's current Buyback Yield % is 0.00. Based on the distribution chart, Nxera Pharma Co ranks #999999 out of 744 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nxera Pharma Co has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nxera Pharma Co ranks #999999 out of 744 companies for Buyback Yield %. This places Nxera Pharma Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Nxera Pharma Co (FRA:JSS) has a current Buyback Yield % of 0.00. The stock's GF Value™ is €6.99, compared to a current price of €5.10 — trading 27% below its estimated fair value. The current Buyback Yield % is 0.00. Nxera Pharma Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Nxera Pharma Co (FRA:JSS), the current Buyback Yield % is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nxera Pharma Co (FRA:JSS) Overvalued in 2026?
Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued.
The current stock price of €5.10 is trading 27% below its estimated GF Value™ of €6.99.
Key valuation signals for FRA:JSS:
Buyback Yield %: 0.00
GF Value™: €6.99 vs. price of €5.10 (27% below fair value)
No single metric tells the full story. See the FRA:JSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
73GF Score
Get the complete analysis for FRA:JSS
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JSS has been successfully added to your 
